The UK's most complete GLP-1 guide
Every Question Answered. Every Side Effect Explained.
- How GLP-1 medications work
- Mounjaro vs Wegovy compared
- Injection instructions
- Side effects & solutions
- What to eat on treatment
- FAQs answered
Free tracker included with every download this week
How Mounjaro Affects the Pancreas — Comparison with Wegovy
Mounjaro (tirzepatide) is a prescription-only weight management injection that works through dual GIP and GLP-1 hormone pathways. If you're concerned about how Mounjaro might affect your pancreas, it's important to understand the mechanism behind this medication and how it compares to alternatives like Wegovy. Both are licensed weight loss injections in the UK, but they work differently. This guide explains the pancreatic effects, safety profile, and how to discuss concerns with your prescriber.
10,000+ calculations today · NHS-aligned thresholds · 100% free
Calculate Your BMI Instantly
Enter your height and weight below. Supports both imperial (stone & lbs) and metric (kg). Results include NHS category, healthy weight range, and ethnicity adjustments.
What Is BMI and Why Does It Matter?
Body Mass Index (BMI) is the most widely used screening tool for assessing whether your weight falls within a healthy range. Used by the NHS, GPs, and weight management services across the UK, BMI provides a quick snapshot of your weight relative to your height. The formula is simple: your weight in kilograms divided by your height in metres squared (kg/m²).
While BMI isn't a perfect measure — it doesn't account for muscle mass, bone density, or fat distribution — it remains the standard first step in identifying potential weight-related health risks including type 2 diabetes, cardiovascular disease, high blood pressure, and certain cancers.
The NHS also recommends adjusted thresholds for people of South Asian, Chinese, or Black African heritage — a BMI of 23 or above is classified as overweight, and 27.5 as obese. Our calculator includes this adjustment as a one-click toggle.
How Mounjaro Works: GIP, GLP-1, and Pancreatic Function
Mounjaro is a dual GIP and GLP-1 receptor agonist — it mimics two natural gut hormones rather than one. This dual mechanism supports appetite regulation and blood sugar control through different pathways than Wegovy (which is a GLP-1-only agonist). The pancreas is involved in weight regulation and insulin secretion, so understanding how these medications interact with pancreatic function is important for informed decision-making.
Key mechanism differences:
- Mounjaro activates both GIP and GLP-1 receptors — the dual action
- Wegovy activates GLP-1 receptors only
- Both slow gastric emptying and support satiety signals to the brain
- Both may support insulin secretion in response to food (a pancreatic function)
Clinical trials (SURMOUNT-1) showed Mounjaro may help participants lose an average of 15–21% body weight over 72 weeks, though individual results vary significantly. The STEP trials for Wegovy (semaglutide) showed approximately 14.9% average body weight loss.
Clinically BackedWeight Loss
No appointments. No waiting rooms. Just care — from a UK-regulated online pharmacy.
How It Works
Three simple steps to understand your weight and take action.
Enter your height and weight in our free calculator. Get your BMI, NHS category, healthy weight range, and ethnicity-adjusted thresholds instantly.
If your BMI suggests you're overweight or obese, explore our GLP-1 calculators to project potential weight loss on Mounjaro or Wegovy.
Use our progress tracker to log your weight weekly, visualise your journey with charts, and stay motivated — all stored privately in your browser.
Free Weight Loss Tools & Guides
Everything you need to understand your weight, explore medication options, and track your progress — completely free.
Pancreatic Safety: What You Need to Know
Neither Mounjaro nor Wegovy directly damage the pancreas, but both carry a rare risk of acute pancreatitis — inflammation of the pancreas. This risk is uncommon but serious. Seek immediate medical attention if you experience severe, sudden stomach pain that radiates to your back, especially in the upper abdomen.
Both medications slow how quickly food leaves the stomach. In rare cases, this could theoretically cause issues if someone has severe gastroparesis (stomach paralysis), but this is not a contraindication to treatment. Your GP or prescriber will assess your individual risk during clinical assessment. If you have a history of pancreatitis or gallbladder problems, inform your prescriber before starting either medication.
Your eligibility for either medication depends on your BMI, health history, and individual assessment — not on the mechanism alone. Both require a UK prescription following clinical evaluation. Use our free GLP-1 weight loss calculator to explore projected outcomes, and our BMI calculator to understand your current health context. These tools help you prepare informed questions for your GP or prescriber about which medication might suit you best.
- Dual GIP/GLP-1 receptor agonist
- Up to 22.5% body weight loss (SURMOUNT-1)
- Weekly injection, dose escalation over 20+ weeks
- Available via private prescription in the UK
- Doses: 2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg
- GLP-1 receptor agonist
- Up to 15–17% body weight loss (STEP trials)
- Weekly injection, 5-step dose escalation
- NHS & private prescription available
- Doses: 0.25mg → 0.5mg → 1mg → 1.7mg → 2.4mg
Mounjaro vs Wegovy: Head-to-Head
A side-by-side comparison of the two most popular GLP-1 weight loss medications available in the UK.
| Feature | Mounjaro | Wegovy |
|---|---|---|
| Drug class | Dual GIP/GLP-1 agonist | GLP-1 agonist |
| Active ingredient | Tirzepatide | Semaglutide |
| Avg. weight loss | 15–22.5% | 12–17% |
| Key trial | SURMOUNT-1 (2022) | STEP 1 (2021) |
| Max dose | 15 mg weekly | 2.4 mg weekly |
| Escalation period | 20–32 weeks | 16–20 weeks |
| Administration | Weekly injection (pen) | Weekly injection (pen) |
| NHS availability | Private prescription only | NHS & private |
| Approx. private cost | £150–£250/month | £150–£300/month |
| Common side effects | Nausea, diarrhoea, constipation | Nausea, vomiting, diarrhoea |
Data sourced from SURMOUNT-1 and STEP 1 clinical trials. Costs are approximate and vary by provider. Always consult a prescriber.
Am I Eligible for Weight Loss Medication?
In the UK, eligibility for GLP-1 weight loss medications like Mounjaro and Wegovy is based on your BMI and overall health profile.
- BMI of 30 or above (obese)
- Age 18 or over
- No contraindicated conditions
- Committed to lifestyle changes
- BMI of 27 or above
- Plus type 2 diabetes
- Or high blood pressure
- Or obstructive sleep apnoea
Use our BMI calculator to check whether your BMI falls within the eligible range.
How We Built These Tools
Every calculator and guide on myweightcheck is built with accuracy and transparency in mind. Our BMI calculator uses the standard WHO formula with NHS-aligned category thresholds. Our GLP-1 projections are modelled on published clinical trial data from SURMOUNT and STEP studies.
All data stays on your device. We don't require sign-ups, and we don't store your health information on any server. Your progress tracker saves data locally in your browser using localStorage, so only you can see it.
We're based in the UK and our tools are designed specifically for UK users — supporting stone & lbs by default, referencing NHS guidelines, using NICE-approved medication data, and linking to GPhC-registered pharmacies.
Frequently Asked Questions
Common questions about BMI, weight loss medications, and our free UK tools.
Does Mounjaro damage the pancreas?
No — Mounjaro does not directly damage pancreatic tissue. However, like all GLP-1 and GIP/GLP-1 medications, there is a rare risk of acute pancreatitis (inflammation). This risk is uncommon but serious. Seek immediate medical attention if you experience severe stomach pain radiating to your back. Your prescriber will assess your individual risk during clinical assessment.
Is Mounjaro safer for the pancreas than Wegovy?
Both Mounjaro and Wegovy carry the same rare pancreatitis risk — there is no evidence that one is safer than the other in this regard. The choice between them depends on mechanism of action, your health history, and your prescriber's clinical judgment. Neither is contraindicated based solely on pancreatic safety concerns.
What are the main differences between Mounjaro and Wegovy?
Mounjaro is a dual GIP and GLP-1 agonist, while Wegovy is GLP-1-only. Clinical trials showed Mounjaro may help with slightly higher average weight loss (15–21% vs 14.9%), though results vary. Mounjaro is once-weekly via KwikPen; Wegovy is also once-weekly. Both require prescription and clinical assessment. Your prescriber will recommend the most suitable option based on your individual health.
Can I take Mounjaro if I have a history of pancreatic problems?
If you have a history of pancreatitis, gallbladder problems, or other pancreatic conditions, you must inform your prescriber before starting Mounjaro or any weight loss injection. Your prescriber may recommend additional monitoring or an alternative approach. Never start any prescription medication without disclosing relevant medical history — clinical assessment is essential.
How do I know if Mounjaro or Wegovy is right for me?
Eligibility depends on your BMI, weight-related health conditions, and individual assessment. Both are prescription-only and require a consultation with a UK-licensed prescriber. Your GP or private prescriber will discuss your medical history, assess risks and benefits, and recommend the most appropriate medication. Use our free BMI calculator to understand your current health context before your consultation.
Ready to take control of your weight loss journey?
Start with a free BMI check, explore your GLP-1 options, or begin tracking your progress today. No sign-up. No cost. Just results.